Elosulfase Alfa

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share (EPS) Addition of GALAFOLD® and POMBILITI® + OPFOLDA®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2026. "This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026. Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations." Mr. Hardy added, "With our larger, more diversified commercial portfolio of innovative medicines, we are positioned to deliver additional growth and increased profitability. We expect strong execution through the remainder of 2026, bringing together our expanded portfolio, scale and disciplined integration efforts to reach more patients living with serious genetic conditions around the world." 2026 Business and Pipeline Highlights Innovation BioMarin recently submitted its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia. If approved, VOXZOGO would be the first targeted therapy for the treatment of hypochondroplasia, with a potential 2027 launch. The company plans to provide an update on the application status as part of its third quarter earnings update. In May, the company announced that the Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint, with a statistically significant increase in annualized growth velocity (AGV) at week 52 versus placebo (LS mean difference +2.33 cm/yr, p<0.0001), along with significant improvements in standing height, height Z-score, and the key secondary endpoint of arm span. The full Phase 3 dataset will be shared in a late-breaking oral presentation at the European Society for Paediatric Endocrinology Annual Meeting in September. In June, at the Endocrine Society Annual Meeting (ENDO 2026), a Phase 2 investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia showed sustained improvements in growth with a favorable safety profile. Mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) and remained above baseline through year three, with mean height standard deviation score (SDS) improving 0.72 over the three years. Also at ENDO 2026, the company presented Phase 1 data for BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia. In a single-ascending-dose study in healthy adults, BMN 333 demonstrated sustained exposure supporting weekly dosing and was well tolerated, with free CNP exposure at the highest dose more than 13-fold that of another long-acting CNP agent, reflecting its potential to become a new standard of care in achondroplasia. The Phase 2/3 study is enrolling, with a data update expected in 2027. In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027. In the second quarter, the European Commission approved PALYNZIQ® for adolescents 12 years and older with phenylketonuria (PKU). PALYNZIQ is the only therapy that enables people with PKU to reach physiologic Phe levels while reducing dietary restrictions, regardless of severity. During the quarter, BioMarin added BMN 820 (formerly DMX-200) to its portfolio, a first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis (FSGS) for which BioMarin holds exclusive U.S. commercialization rights. BMN 820 has the potential to treat a broad FSGS population, regardless of nephrotic syndrome status, and represents a U.S. total addressable patient population of approximately 30,000. The Phase 3 ACTION 3 trial is ongoing, with pivotal data expected in 2028. BMN 351, BioMarin's Phase 1/2 candidate for Duchenne muscular dystrophy, continued in development. The company expects to provide a program update by year-end. Following the pivotal ENERGY 3 trial results, previously announced in May, in which BMN 401 did not meet one of its two co-primary endpoints for the treatment of ENPP1 deficiency, BioMarin has now made the decision to discontinue development of BMN 401 across all indications. In July, BioMarin and the n-Lorem Foundation entered a collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare neurodevelopmental condition with no approved targeted therapies. ReNU syndrome has an expected global population of approximately 100,000. Growth BioMarin expects peak revenue for GALAFOLD to be approximately $1.4 billion by the mid-2030s and for POMBILITI + OPFOLDA to be approximately $1.2 billion by the mid-to-late-2030s. BioMarin expects these high growth therapies to benefit from its global scale and proven commercial capabilities. Metabolic Conditions (formerly Enzyme Therapies) revenue grew 25% Y/Y in the second quarter of 2026, driven by the additions of GALAFOLD and POMBILITI + OPFOLDA and continued strength from PALYNZIQ. The number of patients on therapy grew across all BioMarin-marketed therapies, both Y/Y and sequentially. Strong U.S. and global demand led to increased full-year 2026 VOXZOGO revenue guidance to a low end of $1 billion. The number of children being treated with VOXZOGO globally increased by more than 20% Y/Y in the second quarter. In the U.S., the majority of new patient starts were under two years of age, and the region drove approximately 25% of total VOXZOGO revenue during the quarter. Value Commitment As part of the acquisition of Amicus, which closed on April 27, 2026, the company identified approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an approximately 50% reduction from Amicus-reported 2025 GAAP and Non-GAAP operating expenses, respectively. Synergies reflect a reduction of Amicus' legacy labor costs and external spend and are expected to be largely driven by general and administrative functions, with the large majority of sales and marketing capabilities retained to support continued commercial growth. GALAFOLD and POMBILITI + OPFOLDA, combined, are expected to reach over 60% Non-GAAP Operating Margin by 2030. The company is targeting gross leverage below 2.5 times by mid-year 2027, an acceleration by approximately one year of prior timeline guidance provided at deal announcement, supported by profitability growth of the combined company. Second Quarter 2026 Financial Highlights Total Revenues for the second quarter of 2026 were $990 million, an increase of $165 million compared to the same period in 2025, primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired from Amicus on April 27, 2026, as well as new patients initiating VOXZOGO therapy across all regions and growth in U.S. patients treated with PALYNZIQ. These increases were partially offset by lower VIMIZIM® revenue due to the timing of large government orders outside the U.S. and lower ALDURAZYME® sales volume due to the timing of order fulfillment to Sanofi. GAAP Net Income for the second quarter of 2026 decreased to $45 million compared to $241 million for the same period in 2025. The decrease was primarily driven by the acquisition of Amicus, including integration and restructuring costs, intangible asset amortization, interest expense from debt issued to finance a portion of the transaction, and amortization of inventory fair value step-up. Other drivers included higher sales and marketing spend to support newly acquired products and global expansion of VOXZOGO and higher Research and Development (R&D) spend related to BMN 401, which was acquired in the third quarter of 2025, partially offset by higher gross profit driven by revenue growth as described above. Non-GAAP Income for the second quarter of 2026 decreased to $236 million compared to $282 million for the same period in 2025. The decrease was primarily driven by higher interest expense, higher sales and marketing spend to support newly acquired products and global expansion of VOXZOGO, and higher R&D spend related to BMN 401, partially offset by higher gross profit driven by revenue growth as described above. Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 % Change 2026 2025 % Change Total Revenues $990 $825 20 % $1,756 $1,571 12 % Net Product Revenues by Product: VOXZOGO $253 $221 14 % $472 $435 9 % Metabolic Conditions: VIMIZIM $194 $215 (10) % $405 $404 — % NAGLAZYME® 135 129 5 % 265 243 9 % PALYNZIQ 135 106 27 % 225 199 13 % GALAFOLD 106 — NM 106 — NM BRINEURA® 51 49 4 % 98 89 10 % ALDURAZYME 44 56 (21) % 80 105 (24) % POMBILITI + OPFOLDA 30 — NM 30 — NM Total Metabolic Conditions Revenue $695 $555 25 % $1,209 $1,040 16 % KUVAN® $24 $27 (11) % $48 $52 (8) % ROCTAVIAN®(1) $12 $9 33 % $14 $20 (30) % GAAP Net Income $45 $241 (81) % $150 $426 (65) % Non-GAAP Income (2) $236 $282 (16) % $385 $502 (23) % GAAP Operating Margin % (3) 11.2 % 33.5 % 13.7 % 31.9 % Non-GAAP Operating Margin % (2) 36.4 % 39.9 % 31.0 % 37.9 % GAAP Diluted EPS $0.23 $1.23 (81) % $0.77 $2.19 (65) % Non-GAAP Diluted EPS (2) $1.20 $1.44 (17) % $1.96 $2.57 (24) % NM Percentage change is not meaningful for products acquired from Amicus on April 27, 2026. (1) In 2026, the company announced that it will no longer market ROCTAVIAN. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non-GAAP Diluted EPS along with the related reconciliations to the comparable information reported under U.S. GAAP. (3) GAAP Operating Margin percentage is defined by the company as GAAP Income from Operations divided by Total Revenues. Forward-Looking Non-GAAP Financial Information BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors. Updated 2026 Full-Year Financial Guidance (in millions, except EPS amounts) Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS guidance raised, reflecting strong first-half 2026 performance and second-half 2026 revenue expectations for both Metabolic Conditions and VOXZOGO. Guidance reflects post-close contributions from Amicus beginning April 27, 2026. BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non‑GAAP financial results. Based on current rates, interest expense associated with the financing is estimated at approximately $200 million on an annualized basis, with Term Loans and Senior Notes scheduled to mature after 2030. Item Provided on May 4, 2026 Updated August 6, 2026 Midpoint Growth (Y/Y) Total Revenues $3,825 to $3,925 $3,875 to $3,925 21 % Metabolic Conditions $2,725 to $2,775 Unchanged 31 % VOXZOGO $975 to $1,025 $1,000 to $1,050 11 % Other Revenues(1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.85 to $5.05 $4.90 to $5.10 59 % (1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%. BioMarin will host a conference call and webcast to discuss second quarter 2026 financial results today, Thursday, August 6, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International Dial-in Number: 609-800-9909 Conference ID: 3551298 Conference ID: 3551298 About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. Forward-Looking Statements This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Total Revenues, Non-GAAP Diluted EPS, Non-GAAP Operating Margin, gross leverage, operating cash flow and revenue compound annual growth rate (CAGR) for, in certain instances, the full-year 2026, fourth quarter and second half of 2026, and future periods, and the underlying drivers of those results, such as the expected demand and continued growth of BioMarin's Metabolic Conditions portfolio, including PALYNZIQ, and VOXZOGO, and the expected impact of the acquisition of Amicus Therapeutics, Inc. (Amicus); the anticipated benefits of the acquisition of Amicus, including the expected amount and timing of cost synergies as well as expected revenue from the addition of GALAFOLD and POMBILITI + OPFOLDA, including BioMarin's plans and expectations to accelerate growth through mid-2030s; BioMarin's plans for investment in innovation and future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of BioMarin's product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of BioMarin's commercial products and product candidates, including with respect to the potential new indication for VOXZOGO in hypochondroplasia; and potential growth opportunities and trends, including the assumptions and expectations regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin's product candidates and commercial products. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's success in the commercialization of its commercial products; BioMarin's ability to realize the anticipated benefits of any acquisitions; BioMarin's ability to accurately estimate future financial performance; impacts of macroeconomic and other external factors on BioMarin's operations, regulatory uncertainty, the impact of new or increased tariffs, other trade protection measures, and escalating trade tensions; geopolitical instability, wars and military conflicts; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; BioMarin's ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; BioMarin's ability to meet product demand; actual sales of BioMarin's commercial products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. BioMarin®, VOXZOGO®, VIMIZIM®, NAGLAZYME®, PALYNZIQ®, BRINEURA®, KUVAN®, ROCTAVIAN®, GALAFOLD®, and POMBILITI® + OPFOLDA® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners. BIOMARIN PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three and Six Months Ended June 30, 2026 and 2025 (In thousands of U.S. dollars, except per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 REVENUES: Net product revenues $ 984,393 $ 812,982 $ 1,744,471 $ 1,547,626 Royalty and other revenues 5,315 12,428 11,445 22,929 Total revenues 989,708 825,410 1,755,916 1,570,555 OPERATING EXPENSES: Cost of sales 202,795 150,090 397,794 301,648 Research and development 206,952 161,308 385,748 320,039 Selling, general and administrative 395,549 232,279 653,839 438,395 Intangible asset amortization 73,492 4,846 77,975 9,693 Total operating expenses 878,788 548,523 1,515,356 1,069,775 INCOME FROM OPERATIONS 110,920 276,887 240,560 500,780 Interest income 10,480 18,827 33,040 37,840 Interest expense (63,295) (2,679) (78,253) (5,542) Other income, net 3,279 4,833 7,240 2,879 INCOME BEFORE INCOME TAXES 61,384 297,868 202,587 535,957 Provision for income taxes 16,622 57,336 52,298 109,739 NET INCOME $ 44,762 $ 240,532 $ 150,289 $ 426,218 EARNINGS PER SHARE, BASIC $ 0.23 $ 1.25 $ 0.78 $ 2.23 EARNINGS PER SHARE, DILUTED $ 0.23 $ 1.23 $ 0.77 $ 2.19 Weighted average common shares outstanding, basic 193,423 191,907 192,959 191,440 Weighted average common shares outstanding, diluted 194,467 197,091 194,147 196,643 BIOMARIN PHARMACEUTICAL INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2026 and December 31, 2025 (In thousands of U.S. dollars, except per share amounts) (Unaudited) June 30, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 874,005 $ 1,311,679 Short-term investments — 248,930 Accounts receivable, net 1,061,047 908,214 Inventory 1,782,524 1,298,883 Other current assets 254,047 185,784 Total current assets 3,971,623 3,953,490 Noncurrent assets: Long-term investments — 492,242 Property, plant and equipment, net 989,994 952,508 Intangible assets, net 4,879,367 213,837 Goodwill 655,745 196,199 Deferred tax assets 888,575 1,508,697 Other assets 338,138 277,049 Total assets $ 11,723,442 $ 7,594,022 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,005,793 $ 759,031 Current portion of long-term debt, net 658,203 — Total current liabilities 1,663,996 759,031 Noncurrent liabilities: Long-term debt, net 3,527,939 597,176 Other long-term liabilities 209,815 150,816 Total liabilities 5,401,750 1,507,023 Stockholders' equity: Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively 194 192 Additional paid-in capital 6,037,019 5,956,582 Company common stock held by the Nonqualified Deferred Compensation Plan (11,233) (10,508) Accumulated other comprehensive income (loss) (8,783) (13,473) Retained earnings 304,495 154,206 Total stockholders' equity 6,321,692 6,086,999 Total liabilities and stockholders' equity $ 11,723,442 $ 7,594,022 BIOMARIN PHARMACEUTICAL INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months Ended June 30, 2026 and 2025 (In thousands of U.S. dollars) (Unaudited) Six Months Ended June 30, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 150,289 $ 426,218 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 114,049 40,632 Non-cash interest expense 27,912 1,320 Stock-based compensation 119,152 85,231 Impairment of assets — 2,967 Deferred income taxes 2,261 61,771 Unrealized foreign exchange gains (4,046) (5,306) Other (5,534) (4,633) Changes in operating assets and liabilities, net of effects of business acquired: Accounts receivable, net (46,005) (156,124) Inventory 12,334 (72,462) Other current assets (23,589) (15,092) Other assets 9,005 (13,505) Accounts payable and accrued liabilities 26,265 3,111 Other long-term liabilities 6,667 5,537 Net cash provided by operating activities 388,760 359,665 CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and equipment (49,739) (33,869) Maturities and sales of investments 767,277 195,738 Purchases of investments (25,792) (202,433) Purchase of intangible assets (5,433) (266) Acquisition of Amicus, net of cash acquired (5,067,630) — Other 4,966 — Net cash used in investing activities (4,376,351) (40,830) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercises of awards under equity incentive plans 6,655 7,707 Taxes paid related to net share settlement of equity awards (39,504) (51,089) Proceeds from borrowings 3,650,000 — Payments of debt issuance costs (65,604) — Net cash provided by (used in) financing activities 3,551,547 (43,382) Effect of exchange rate changes on cash (1,630) (4,479) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (437,674) 270,974 Cash and cash equivalents: Beginning of period $ 1,311,679 $ 942,842 End of period $ 874,005 $ 1,213,816 Non-GAAP Information The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non-GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company's equity plans or convertible debt in periods when they are dilutive under Non-GAAP. Projected Gross Leverage is defined by the company as undiscounted debt (total debt excluding unamortized discount and deferred offering costs) as of the balance sheet date divided by 4 quarter projected Non-GAAP Adjusted EBITDA. Non-GAAP Adjusted EBITDA is defined by the company as GAAP Income (or Loss) from Operations excluding the impact of depreciation, amortization and stock-based compensation expense. Non-GAAP synergies is defined by the company as Amicus' legacy labor and external spend cost reductions, excluding the impact of stock-based compensation. BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure. Because these Non-GAAP metrics are important internal measurements for BioMarin, the company believes that providing this information in conjunction with BioMarin's GAAP information enhances investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's principal business. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information: Reconciliation of GAAP Reported Information to Non-GAAP Information (1) (In millions of U.S. dollars, except per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP Reported Net Income $ 45 $ 241 $ 150 $ 426 Adjustments Stock-based compensation expense - COS 5 4 9 6 Stock-based compensation expense - R&D 16 14 28 26 Stock-based compensation expense - SG&A(2) 55 30 83 53 Amortization of intangible assets 73 5 78 10 Amortization of acquired inventory step-up(3) 12 — 12 — Acquisition-related costs(3) 84 — 84 — Severance costs (4) 3 — 12 — Loss on investments (5) — — — 3 Income tax effect of adjustments (57) (11) (70) (22) Non-GAAP Income $ 236 $ 282 $ 385 $ 502 Three Months Ended June 30, 2026 2025 COS R&D SG&A COS R&D SG&A GAAP expenses $ 203 $ 207 $ 396 $ 150 $ 161 $ 232 Adjustments Stock-based compensation expense(2) (5) (16) (55) (4) (14) (30) Amortization of acquired inventory step-up(3) (12) — — — — — Acquisition-related costs (3) — — (84) — — — Severance costs (4) — — (3) — — — Non-GAAP expenses $ 186 $ 191 $ 253 $ 146 $ 147 $ 203 Six Months Ended June 30, 2026 2025 COS R&D SG&A COS R&D SG&A GAAP expenses $ 398 $ 386 $ 654 $ 302 $ 320 $ 438 Adjustments Stock-based compensation expense(2) (9) (28) (83) (6) (26) (53) Amortization of acquired inventory step-up(3) (12) — — — — — Acquisition-related costs (3) — — (84) — — — Severance costs (4) — — (12) — — — Non-GAAP expenses $ 378 $ 358 $ 475 $ 295 $ 294 $ 385 Three Months Ended June 30, Six Months Ended June 30, 2026 Percent of GAAP Total Revenue 2025 Percent of GAAP Total Revenue 2026 Percent of GAAP Total Revenue 2025 Percent of GAAP Total Revenue GAAP Income from Operations $ 111 11.2 % $ 277 33.5 % $ 241 13.7 % $ 501 31.9 % Adjustments Stock-based compensation expense(2) 76 7.7 48 5.8 120 6.8 85 5.4 Amortization of intangible assets 73 7.4 5 0.6 78 4.4 10 0.6 Amortization of acquired inventory step-up(3) 12 1.2 — — 12 0.7 — — Acquisition-related costs (3) 84 8.5 — — 84 4.8 — — Severance costs (4) 3 0.3 — — 12 0.7 — — Non-GAAP Income from Operations $ 360 36.4 % $ 329 39.9 % $ 545 31.0 % $ 596 37.9 % Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP Diluted EPS $ 0.23 $ 1.23 $ 0.77 $ 2.19 Adjustments Stock-based compensation expense(2) $ 0.38 $ 0.24 0.60 0.43 Amortization of intangible assets $ 0.37 $ 0.03 0.39 0.05 Amortization of acquired inventory step-up(3) $ 0.06 $ — 0.06 — Acquisition-related costs(3) $ 0.42 $ — 0.42 — Severance costs (4) $ 0.02 $ — 0.06 — Loss on investments (5) $ — $ — — 0.02 Income tax effect of adjustments $ (0.29) $ (0.06) (0.35) (0.11) Non-GAAP Diluted EPS $ 1.20 $ 1.44 $ 1.96 $ 2.57 Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP Weighted-Average Diluted Shares Outstanding 194.5 197.1 194.1 196.6 Adjustments Common stock issuable under company's convertible debt (6) 4.4 — 4.4 — Non-GAAP Weighted-Average Diluted Shares Outstanding 198.9 197.1 198.5 196.6 (1) Certain amounts may not sum or recalculate due to rounding. (2) Stock-based compensation expense recorded in SG&A for the three and six months ended June 30, 2026, includes approximately $13 million related to the post-combination service period for unvested Amicus stock options. (3) These amounts represent costs resulting from the Amicus acquisition that closed on April 27, 2026. Acquisition-related costs were included in SG&A and consisted of severance, transaction and integration costs. Amortization of acquired inventory step-up was included in COS. (4) These amounts were included in SG&A and represent charges for severance in connection with the company's plan to simplify its organizational design and strategic initiatives in the first and second quarters of 2026. (5) Represents impairment loss on non-marketable equity securities recorded in Other income, net, in the first quarter of 2025. (6) Common stock issuable under the company's convertible debt were excluded from the computation of GAAP Weighted-Average Diluted Shares Outstanding for the three and six months ended June 30, 2026 as they were anti-dilutive. Amicus Therapeutics, Inc. (1) Reconciliation of Non-GAAP Financial Measures (in thousands) (Unaudited) Twelve Months Ended December 31, 2025 Total operating expenses - as reported GAAP $ 528,492 Research and development: Share-based compensation 12,156 Selling, general and administrative: Share-based compensation 75,254 Loss on impairment of assets 1,702 Depreciation and amortization 7,460 Total operating expense adjustments to reported GAAP 96,572 Total operating expenses - as adjusted $ 431,920 (1) The above historical reconciliation is reproduced from Amicus' earnings release furnished as Exhibit 99.1 to its Current Report on Form 8-K dated February 20, 2026 and reflects Amicus' historical definitions of the applicable non-GAAP measures. Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 SOURCE BioMarin Pharmaceutical Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning clinical development, pharmacovigilance and medical affairs, and a track record of advancing and launching enzyme replacement therapies for rare diseases. “Adrian’s proven experience in rare disease drug development will be essential to the work ahead of us at Spruce as we set our sights on a BLA filing for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) in Q4 2026 and prepare for a potential commercial launch,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “Having helped bring multiple enzyme replacement therapies to patients with rare pediatric and genetic disorders, including neurodegenerative disease, Adrian understands the clinical, regulatory and medical complexities of programs like ours. We are delighted to welcome Adrian to our executive leadership team.” Dr. Quartel joins Spruce from Zevra Therapeutics, where he served as Chief Medical Officer and helped guide the clinical development, medical affairs and regulatory strategy for the company’s rare disease portfolio. Prior to Zevra, he was Chief Medical Officer of Acer Therapeutics and Chief Medical Officer of Adamas Pharmaceuticals. Earlier, as Group Vice President of Global Medical Affairs at BioMarin Pharmaceutical, he spearheaded the launch of six treatments for rare diseases and genetic disorders, including the enzyme replacement therapies NAGLAZYME®, VIMIZIM® and Brineura®—the last of which is a therapy for a rare pediatric neurodegenerative disorder. Before BioMarin, Dr. Quartel oversaw clinical development and held senior medical leadership positions at Astellas, Chiltern and ICON Clinical Research. He holds an M.D. from Erasmus University Medical School, Rotterdam, and a postgraduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine. Dr. Quartel is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom. “I am excited to join Spruce at such a pivotal moment for the company and for the MPS IIIB community,” said Adrian Quartel, M.D., FFPM, Chief Medical Officer of Spruce Biosciences. “TA-ERT has the potential to be the first disease-modifying treatment option for children living with this devastating, neurodegenerative disease, for which there are no FDA-approved therapies today. I look forward to working alongside this talented team to advance TA-ERT toward the market with the goal to eventually help patients and families who urgently need new options.” Inducement Award In connection with Dr. Quartel’s employment with Spruce Biosciences, on July 27, 2026, Dr. Quartel was granted restricted stock units (RSUs) for 13,000 shares of Spruce’s common stock. The Compensation Committee of the Board of Directors approved the award as inducement material to Dr. Quartel’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the underlying shares vesting on each anniversary of June 15, 2026, subject to Dr. Quartel’s continued service relationship with Spruce Biosciences through the applicable vesting date. The award will be subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of the applicable award agreement covering the grant. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the impact of new management hires, the fulfillment of Spruce’s strategic business objectives, the planned biologics license application submission for TA-ERT, potential regulatory approval, potential commercial launch of TA-ERT, and TA-ERT’s potential to be the first disease-modifying treatment option for MPS IIIB. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plan,” “will,” “believe,” “could,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.